Objective: In thymomas, World Health Organization (WHO) histology, Masaoka stage and myasthenia gravis (MG) have long been considered important for patient management and outcome. Their role has been independently investigated in the past. Few studies, however, focussed on the correlations among these variables. The aim of the present study was to retrospectively evaluate, in our patient population of resected thymomas, the inter-relationships among MG, WHO histology and Masaoka stage, and to look at how and to what extent one variable is associated with the other two in terms of clinical presentation and survival. Univariate and multivariate survival analysis were also performed using the same covariates. Overall survival (OS) and disease-free survival (DFS) were calculated. Results: MG was associated with early Masaoka stages (odds ratio (OR) 0.45, 95% confidence interval (CI) 0.33-0.62) and B-type thymomas (OR 1.59, 95% CI 1.23-2.05). B-type thymomas were associated with high Masaoka stage (OR 0.46, 95% CI 0.36-0.60). High Masaoka stage was associated with non-MG (OR 3.27; 95% CI 2.00-5.34). In univariate survival analysis, MG ( p = 0.01) and Masaoka stage ( p = 0.0001) were significant prognostic indicators using OS. Using DFS, WHO histology (A/AB vs B1/B2/B3 types) ( p = 0.05) and Masaoka stage ( p = 0.0001) had a prognostic significance. In multivariate analysis, only Masaoka stage was an independent prognostic covariate using OS (hazard ratio (HR) 2.57, 95% CI 1.46-4.52, p = 0.001) and DFS (HR 3.18, 95% CI 1.56-6.52, p = 0.001). Conclusions: In thymomas, MG, WHO histology and Masaoka stage are inter-related. MG has an influence on histology and stage at presentation, while two clinical/histologic patterns are more likely: early Masaoka stage A/AB WHO type and high Masaoka stage/B WHO type. Among the three factors, only Masaoka stage had a prognostic significance on OS and DFS. Our results suggest that a consistent staging system for thymomas should take into account all three variables. #
Introduction
Thymomas are the most common mediastinal neoplasm in adults, representing 50% of the tumours in the anterior mediastinum. Despite their indolent behaviour, thymomas should be considered malignant because of the tendency to local invasion, pleural dissemination and, although rare, systemic metastases. Thymomas are an extremely heterogeneous group of lesions with a wide spectrum of morphologic appearances. When seeing in the global perspective, however, thymomas are relatively uncommon, with an incidence of approximately 3.0/1 000 000 people and care is dispersed across many institutions [1] . For these reasons, thymomas have long eluded efforts by the scientific community to be schematised into those standards adopted for most of other solid-organ tumours, including a validated staging system, histologic classification and prognostic categories. Further, the unique association with myasthenia gravis (MG) and the corresponding clinical and prognostic significance of the association of the two diseases have added E-mail address: enrico.ruffini@unito.it (E. Ruffini).
additional confusion to the already complicated scenario. After decades of debates and proposals, most of which did not stand the test of time, an agreement has been reached in the last years by most authors for histology, staging and classification of MG status. The World Health Organization (WHO) histologic classification issued in 2004 [2] , the Masaoka staging system proposed in 1981 [3] , and later refined in 1994 [4] and the MG classification of the Myasthenia Gravis Foundation of America (MGFA) adopted since 2000 [5] all represent robust and validated classification systems over which all centres may build their datasets. Despite that, relatively few studies have investigated the inter-relationship among these three important variables (WHO histology, myasthenia gravis and Masaoka stage) and how one variable correlates with the other two. The purpose of the present study was to evaluate, using regression models, how WHO histology, MG and Masaoka stage are correlated and to what extent one variable may influence the other two in terms of clinical presentation as well as in the long-term outcome.
Materials and methods
From January 1990 to December 2008, a total of 255 patients were operated upon with a diagnosis of thymoma at our Institution. All patients had histological confirmation of thymoma before surgery. Preoperative assessment in a patient with a suspected thymoma includes routine preoperative blood tests, electrocardiography (EKG), pulmonary function tests with diffusion capacity (diffusion lung capacity for carbon monoxide (DLCO)) and arterial blood gas analysis, computed tomography (CT) scan of the chest and upper abdomen, neurologic consultation in case of associated MG and chest magnetic resonance imaging (MRI) in selected cases. Since 2004, we have started using positron emission tomography (PET) scan (and more recently integrated PET-CT scan) as part of the work-up. Preoperative assessment of resectability is usually undertaken by a senior surgeon in association with the medical oncologist and the radiation oncologist. In case of anticipated unresectability, induction chemotherapy has been used since 2005 followed by resection. Surgery included resection of the thymoma, always associated with total thymectomy. Extended resection to surrounding organs was performed in case of gross involvement, including mediastinal pleura, lung, pericardium and superior vena cava. Our standard surgical approach is a total sternotomy. In case of small encapsulated thymomas, a partial sternotomy was used. A thoracotomic approach was used in case of lateral extension of the thymoma or in case of pleural involvement. In case of thymomas extending laterally to the lung or the pericardium, a combined sternotomy + thoracotomic approach was employed.
All thymomas were histologically classified based on the most recent WHO classification [2] . In case of composite thymomas (with more than one component A or B), our policy is as follows: in case of AB thymoma, if the combined component is B1, we report the case as AB thymoma; if the combined component is B2 or higher, the thymoma is classified and analysed according to the highest B component; in case of combined B categories, mostly B2/B3, we classify and analyse the thymoma according to the most pejorative B category. We excluded from the analysis type C thymomas (formerly known as thymic carcinomas). For the purpose of the analysis, we graded the histologic types using an ordinal scale proceeding from A to B3. The tumour stage was determined according to the Masaoka classification [3] . MG was graded following the guidelines of the Medical Scientific Advisory Board of the MGFA [5] .
Postoperative radiotherapy was employed in invasive thymomas (stages II through IV), although we recently decided not to offer radiation therapy to stage II WHO A-B1 thymomas. Recurrence of thymoma was divided into local (in the bed of the resected thymus or thymoma), regional (intrathoracic, excluding recurrence into the lung) and distant (extrathoracic or intraparenchymal into the lung). Follow-up schedule included 6-month CT scan for the first 3 years and a yearly CT scan afterward.
Data of patients' outcome were obtained from hospital records and telephone interviews to patients, relatives or the family practitioners.
The study was approved by our institutional review board and the use of anonymous data was permitted as part of an observational study.
The inter-relationship among the three variables of interest, WHO histology, Masaoka stage and MG, was assessed using regression analysis. When the outcome variable was ordinal (Masaoka stage and WHO histology), ordinal regression was used and the cumulative logit model was employed. When the outcome variable was categorical, a logistic regression (logit) model was used. Both overall survival (OS) and disease-free survival (DFS), defined as freedom from recurrence in case of complete resection (R0) or as time-toprogression in case of incomplete recurrence (R1-R2), were employed. Survival analysis was undertaken using the Kaplan-Meier method for actuarial survival. Differences between survival rates were tested using the log-rank method. Cox's proportional hazard model was employed to assess the independent significance of each covariate. Odds ratio (OR), hazard ratios (HRs) and the corresponding 95% confidence intervals (95% CIs) were provided for each model. A p value less than 0.05 was considered significant. All analysis was performed using STATISTICA (Statsoft, Italy, release 7.1) software. Table 1 illustrates the patients' characteristics. The study included 127 men and 128 women with a median age of 55 years (SD AE 14 years, range . MG was present in 105 patients (41%). Overall, a total resection was undertaken in 223 patients (87%). In Masaoka stage III, 61 patients had involvement of the mediastinal pleura, 45 of the pericardium, 43 of the lung and 10 of the great vessels. Overall, a recurrence was observed after total resection at follow-up in 24 patients (9%). Recurrence was local in nine patients, regional in 13 and distant in two. Follow-up was complete in 240 cases (94%). At the completion of follow-up (December 2008), 40 patients were dead (16%), of whom 15 from thymoma, six from MG and 19 from other causes. 
Results

Regression analysis
Survival analysis
Survival analysis was performed using both OS and DFS as measures of outcome, and each variable of interest was analysed both in a univariate and multivariate model. As for MG, using OS, the presence of MG confers a significant survival advantage. Ten-year survival rates were 82% and 62%, respectively, in the patients with and without MG ( p = 0.001). When stratified by stage, a significant OS difference was only observed in Masaoka stage I (100% vs 80% in MG and non-MG patients, respectively, at 10 years, p = 0.02). Using DFS, the difference was not found to be significant either overall (86% vs 69%, p = 0.11) (Fig. 1) , or when breaking down by stages. As for WHO histology, using OS as outcome measure, 5-year survival rates in A, AB, B1, B2 and B3 types were 90%, 92%, 81%, 88% and 70%, respectively ( p = 0.56). Five-year survival rates in A-type and B-type thymomas were 91% and 84% ( p = 0.55). When using DFS, survival rate differences among the five histologic types were more evident (100%, 94%, 84%, 86% and 88% respectively, p = 0.08) (Fig. 2 ), and reached a significance level when we compared A-type versus B-type thymomas (96% and 84%, p = 0.05) (Fig. 3) . Finally, for Masaoka stage, OS rates by stage (I-IV) were highly significant either using OS (97%, 98%, 83% and 35, respectively, p = 0.0001) or DFS (100%, 98%, 98%, and 35% respectively, p = 0.0001) (Fig. 4) . Multivariate survival analysis using the Cox's proportional hazard model was performed on the patients receiving total resection (to offset the potential bias of the strong independent significance of the extent of resection on survival) and differently, using OS and DFS as outcome measure. In both cases, we found that among the three variables of interest, Masaoka stage was a strong independent prognostic indicator (using OS: HR 2.57, 95% CI 1.46-4.52, p = 0.001; using DFS: HR 3.18, 95% CI 1.56-6.52, p = 0.001), while MG (using OS: HR 0.93, 95% CI 0.38-2.31, p = 0.88; using DFS: HR 1.69, 95% CI 0.60-4.70, p = 0.31) and WHO histology (using OS: HR 1.17, 95% CI 0.70-1.98, p = 0.55; using DFS: HR 1.10, 95% CI 0.58-2.07, p = 0.77) were not.
Discussion
The main objective of the present study was to assess, using regression models, how and to what extent in patients with thymoma MG, WHO histology and Masaoka stage interrelate one another in the clinical presentation and in the long-term outcome.
The results of our study indicate the following correlations: (1) a myasthenic status correlates with early Masaoka stages and B-type thymomas; (2) higher Masaoka stages correlate with B-type thymomas and a non-myasthenic status; (3) when moving from A to B3 types, an increased [ ( ) T D $ F I G ] Masaoka stage and a myasthenic status is more likely; and (4) among the three variables of interest, only Masaoka stage was an independent prognostic factor in a multivariate regression model. Among other solid organ neoplasms, thymoma has long represented a challenge, evading most of the generally accepted rules, which form the basis of our scientific approach to neoplasms, including a valid histologic classification and an effective staging system. Further, the unique association with a distinct clinical entity, MG, makes the situation more complicated, and, over the past 3 decades, a number of authors have reported their experience with conflicting and sometimes opposite conclusions. A general consensus has been reached in the recent years that four factors play a role in the management and outcome of thymomas: the completeness of resection, the Masaoka stage, the WHO histologic classification and MG [6, 7] . Unfortunately, every effort to reunite them in a validated staging system (similar to what has been done in lung cancer) has failed so far, and the four factors play their role independently.
The association between thymoma and MG has long represented a challenge, and no report on thymoma may ignore the presence of MG and vice versa.
Until the 1970s [8] , MG was uniformly regarded as an indicator of poor prognosis. After the 1980s, MG was no longer considered an adverse prognostic factor, and many reports agreed that thymoma patients with MG have an equal or even better survival than those without it [9, 10] . This change of perspective is due to several factors including improvement in the management of MG, an earlier diagnosis of thymoma in patients with MG and the hypothetical beneficial effect of steroids, used in both diseases. In a clinical review from Japan of more than 1000 patients with thymoma, Kondo and Monden [11] observed that thymomas with MG were at earlier stages and showed lower recurrence rates than those without MG, although they did not find any difference in OS either overall or in stage III patients, while they observed a significant survival difference in stage IV patients. They conclude that thymomas with MG are equally or less malignant than those without MG. In a recent report, Margaritora and colleagues [12] , out of more than 300 patients, found a significant survival advantage in thymoma patients with MG, which was evident both using OS and DFS; in the same report, they pointed out that no correlation exists in their series between stage and MG. Others, however, observed that [11, 13, 14] when adjusted by stage, no survival difference exists between the two groups. One of the reasons to explain the better survival in MG-thymoma patients is a possible correlation between stage and MG. Indeed, a correlation between MG and early stages of thymomas has been reported variously in the literature [11, 15, 16] . This might result from the earlier diagnosis of thymoma in MG patients due to their stricter follow-up. Others [17] , however, supporting the observation that invasive thymomas are diagnosed more frequently in non-MG patients, postulated that thymoma with and without MG are two distinct diseases, and a biologically more aggressive pattern of growth of thymoma in patients without MG may be responsible for the different presentation, outcome and recurrence rates as compared with thymoma and MG. The situation becomes further complicated when considering the inter-relationship between MG and histology. A correlation between MG and B-type thymomas has been reported by some authors [13, 15, 18] , although some series found a correlation only with B1 and B2 but not B3 [12, 15] . Histologically, the association between thymoma and MG has been related to the generation of mature T cells from the thymoma. Abnormal regulation of lymphocytes within the thymus gland can result in autoimmunity (MG) or immunodeficiency (hypogammaglobulinaemia, T-cell deficiency syndrome). According to the WHO classification, A-type thymomas are composed mainly of neoplastic spindle-shaped epithelial cells without atypia and without lymphocytes; ABtype thymomas are similar to A-type but have some foci of lymphocytes; and B-type thymomas consist of plump epitheliod neoplastic cells with a component of T lymphocytes at different stages of maturation. Okumura and colleagues [18] studied the clinical and functional significance of WHO classification on 146 thymomas. They found an increased proportion of tumour-associated lymphocytes in AB, B1 and B2 thymomas, and an increased MG prevalence in type B1 and B2 tumours. Further, they observed that a thymic cortical epithelial cell function was well represented in B1, AB and B2 tumours. The authors, therefore, correlate the association with MG to the functional aspects of thymomas. They further speculate that pathogenesis of MG seems to result from the epithelial function to induce T-cell development. This, in turn, might explain the association between MG and the B-type thymomas, which are to be considered as functional tumours in terms of inducing T-cell maturation.
Our results match those of the literature, confirming a strong correlation between MG and B-type thymomas and between MG and early stages. Prognostically, although a significant OS advantage was evidenced in patients with MG, the difference greatly reduced although maintaining a trend; however, it lacked statistical significance when using DFS and multivariate regression models and when stratified by stage. It seems difficult therefore to sustain, from our experience, that thymomas with and without MG are two different clinical entities.
Since the publication of the WHO histologic classification of thymomas in 1999, that was later refined in 2004, a number of reports were published to validate its use and to confirm its prognostic relevance with conflicting results. Although most series agree that a survival decrement occurs when proceeding from A to B3 types, some authors argued that the slight survival difference between some subgroups, notably A and AB and B1 and B2, would justify a simpler classification into three histologic groups, A/AB, B1/B and B3 [19] . Indeed, after an initial enthusiasm, recent reports cast doubts on the validity of the 2004 revision as an effective prognosticator. Okumura and colleagues [13] , in 139 patients with thymoma, found a similar survival among patients with A, AB and B1 types. Similarly, in a recent report, Okereke and colleagues [14] were unable to demonstrate differences in DFS among standard WHO classes or any combination of these. The authors claim that the potential for inter-observer variability in their study was minimised by a consensus opinion between their pathologists. Indeed, despite clear diagnostic criteria, the WHO classification has been associated with an overall moderate level of agreement with well-recognised intra-and inter-observer discrepancies [20] , particularly among pathologists with limited experience. Most of the discrepancies are related to group B and AB types [21] . Our results, using an ordinal regression model, indicate that a significant correlation exists between A-type-Masaoka early stage MG and B-type-Masaoka high stage non-MG. Further, when using DFS in the survival analysis, WHO histologic classification showed a trend towards a prognostic significance, which indeed reached significance levels when the five original histologic classes (A, AB, B1, B2 and B3) were combined in two (A type vs B type). Ours and most recent reports thus indicate that a revision of the current histologic classification, taking into account reproducibility and practicality, is needed to validate histology as a prognosticator in the future staging system.
There is no official recognition by International Union Against Cancer (UICC) or American Joint Committee on Cancer (AJCC) of a staging system for thymoma. Several different proposals were put forward in the past, including a tumour, node, metastasis (TNM)-like system [22] and a French GETT (Group d'Etude des tumours Thymiques) version [23] . Only the surgical-pathologic staging system proposed by Masaoka in 1981 [3] , later revised by Koga in 1994 [4] , has eventually stood the test of time. The system has consistently been used through the decades and has proved to be a strong outcome predictor. As with other staging systems, some problems have arisen, calling for a revision of the system. First, it is a pathologic staging system, defined after resection; indeed, similar to other solid-organ tumour staging, that is, lung cancer, a clinical staging system is of utmost importance, particularly because surgery sometimes is not the first step in the treatment. Unfortunately, no agreement has been reached as to objectively define, using standardised criteria, the stage before surgery, and this indeed represents a flaw in the current thymoma staging. Second, the present MasaokaKoga staging does not take into account the size of the tumour, which, similar to what we have learned from lung cancer, has been reported to be of importance by some authors [19, 24] . Third, although rare, involvement of lymph nodes may occur in thymomas, thymic carcinomas and neuroendocrine thymic tumours; and, currently, there is no clear indication as to which Masaoka stage should lymphnode involvement belong. Further, a more objective indication of R0 resection and peritumoural invasion and invasion to surrounding organs needs to be established. Last, but not least, a more uniform definition and classification of thymoma recurrence is lacking, and many authors have reported different results upon using different definitions and classifications of recurrence [25] .
Most of the results and conclusions drawn in the past on thymomas about prognostic significance of different variables on outcome came from the interpretation of OS, which is concrete, easy to verify and is certainly an adequate measure of outcome in most aggressive cancers, where death is almost always caused by the neoplasm, and survival after a recurrence is generally short (lung cancer and mesothelioma). Indeed, OS should always be reported as a general overview of the long-term survival in the study population. Thymomas, however, are often slow-growing malignancies, and, even in higher stages, death may be caused by other causes, by the associated MG, and many patients may experience a prolonged survival after a recurrence. For these reasons, many authors now advocate the use of more specific measures of outcome in most oncological articles, and among others, DFS seems to be the most appropriate. Indeed, in the present study, we employed both survival indicators, and, as expected, results were different according to the used survival indicator. In univariate OS analysis, the presence of MG and Masaoka stage were both significant predictors of long-term survival, while in univariate DFS analysis, WHO histology (particularly when using the A-vs B-type comparison) and Masaoka were significant prognostic factors. Of note, however, using Cox's regression models, only Masaoka stage was a significant covariate upon using either OS or DFS.
In Our results suggest that a consistent staging system for thymic malignancies should take into account all the three variables, which until now have been considered independently.
Appendix A. Conference discussion Dr F. Detterbeck (New Haven, CT): This is a sizable group of patients. I think it is a nice analysis of how there is a correlation between different aspects, the myasthenia, the stage and the WHO type. This is something that has been noted in other papers as well but not analysed as nicely.
Personally I am making progress in my understanding of statistical analyses, and I think that is important for all of us. There are many studies of prognostic factors. In some areas it is more refined. In thymic malignancies it is generally not very refined. It is generally something that some people call a phase 1 study of prognostic factors, which is when you take patients and you look at many factors and you come up with things. You come up with, for example, that people that put their left shoe on first have better survival, because, of course, if you look at enough factors, you will come up with some things by chance alone. So many analyses of prognostic factors are just phase 1 explorations that really need validation and other studies.
However, I would say that many of your findings are corroborated by other studies. So I think we do have validation. I have not seen it really analysed before, though, whether myasthenia has a particular meaning in disease-free survival. So I think this is something that we should look for external validation on; at least I am not aware of it.
Another factor that I think is worth pointing out is that you really need a fair number of patients in order to do valid multivariate analyses of outcomes. It depends on multiple factors. It depends on how big your effect size is of a particular variable. If you have a large effect size, you don't need as much, but for a small effect size, you need much more. This is a nice study of around 258 patients, but for a small effect size looking at three variables -for example, myasthenia, stage, and WHO histology -you would actually need approximately 540 patients. So that is something that I think we haven't paid enough attention to.
But having said that, I think this is a very nice analysis. I have a couple of questions.
First, it is still not entirely clear to me how you factored in completeness of resection and perhaps you can make a statement about that. Another exploratory question I have is that it seems to me that over time, some things have changed. So at one point in time myasthenia was correlated with worse survival, and I think that is because patients were dying of myasthenia. Now we have better care and it is much less common for people to die of myasthenia and I think that it doesn't correlate anymore. I think that the same effect may be happening with regards to myasthenia and stage. I think with a greater prevalence of CT scanning, there are probably more patients with myasthenia that are found to have a thymoma than there were at a previous time, and I wonder if you might look at your series over time to see if there was a trend showing that correlation of myasthenia and early stage patients changed over time. That might be just an interesting thing to look at.
And finally, I want to make just a small pitch for ITMIG. That is the International Thymic Malignancy Interest Group. For anyone who is interested in this disease, we would very much like to have their participation. If you go to www.itmig.org, you can sign up and then receive updates and information and get involved.
Dr Ruffini: As far as myasthenia is concerned, we were probably one of the first centres back in the 90's, thanks to my former chief, Professor Maggi, to demonstrate that myasthenia indeed was not an adverse prognostic factor. In the past, there were a few reports saying that myasthenia was indeed a negative prognostic factor. We interpreted these results because probably myasthenic patients are diagnosed earlier. But when we looked t the literature, other authors say that probably thymoma with myasthenia gravis and thymoma without myasthenia gravis are two different entities. Probably there is no definite answer to date. And I think that only with collaborative efforts, if we unite all the thymic community, this would be the answer, because we would be able to collect as many patients as possible. As Frank said, to demonstrate a sizable effect, we need a very large number of patients, and the more variables there are, the more we need many patients. So probably this is the message I would like to give you, to join the thymic community to collect as many patients as possible.
As far as completeness of resection is concerned, when we looked at the correlation between the variables, probably the completeness of resection was irrelevant, because we just correlated the variables, but when we look at the prognostic impact, as I said, I took out incomplete resection and so I considered only the total resections. I hope I have answered your questions.
Dr F. Venuta (Rome, Italy): You have clearly demonstrated the limitations of the variables that we use to assess prognosis of our thymoma patients, and in particular the WHO classification; there are clear limitations and this classification should be revised. There are also inter-observer problems, as witnessed by the argument between European and American pathologists. We have started to look at this classification, paying attention to what Suster and Moran are doing in the United States. We have found that a different grouping from what you have done may help; in particular grouping B2 and B3 together and leaving B1 at a lower stage. We had some interesting results that are much more encouraging in assessing prognosis. Do you have any clue about that? Did you try different strategies to group these patients or did you just do this type of straightforward analysis?
Dr Ruffini: We tried to group the five types as indicated by the WHO. You know that in the past Suster and Moran suggested a simplified histological classification into three types, typical, atypical, and thymic carcinomas. Other authors proposed a classification into A (A, AB) early B (B1, B2) and advanced (B3) thymomas. So every author has tried to lump together these five types, and the only significant difference we found was when we grouped together A, AB and B types. The problem is how to consider the C type and the B3 type. So we decided to take off the C type, that is, the thymic carcinoma; probably thymic carcinoma is a completely different entity, and these are our results. The only difference we found was when
